Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

EFFECT OF CONVALESCENT PLASMA ON MORTALITY IN PATIENTS WITH COVID-19 PNEUMONIA

Martín R. Salazar, Soledad E. González, Lorena Regairaz, Noelia S. Ferrando, Veronica V. González Martínez, Patricia M. Carrera Ramos, Laura Muñoz, Santiago A. Pesci, Juan M. Vidal, Nicolas Kreplak, Elisa Estenssoro
doi: https://doi.org/10.1101/2020.10.08.20202606
Martín R. Salazar
1Teaching and Research Service, San Martín Hospital, La Plata, Buenos Aires, Argentina
2Faculty of Medicine, National University of La Plata, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mrsalazar@med.unlp.edu.ar
Soledad E. González
3Ministry of Health of the Province of Buenos Aires, La Plata, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lorena Regairaz
4Immunology Unit. Children’s Hospital Sor Maria Ludovica, La Plata, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Noelia S. Ferrando
2Faculty of Medicine, National University of La Plata, Buenos Aires, Argentina
5Hemotherapy Institute of Buenos Aires Province “Dra Nora Etchenique”, La Plata, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Veronica V. González Martínez
3Ministry of Health of the Province of Buenos Aires, La Plata, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia M. Carrera Ramos
6Pediatric Research Institute “Prof. Fernando E. Vitieri”, Children’s Hospital Sor Maria Ludovica, La Plata, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura Muñoz
3Ministry of Health of the Province of Buenos Aires, La Plata, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Santiago A. Pesci
3Ministry of Health of the Province of Buenos Aires, La Plata, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Juan M. Vidal
3Ministry of Health of the Province of Buenos Aires, La Plata, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicolas Kreplak
3Ministry of Health of the Province of Buenos Aires, La Plata, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elisa Estenssoro
7Intensive Care Unit. San Martín Hospital, La Plata, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Convalescent plasma, widely utilized in viral infections that induce neutralizing antibodies, has been proposed for COVID-19, and preliminary evidence shows that it might have beneficial effect. Our objective was to compare epidemiological characteristics and outcomes between patients who received convalescent plasma for COVID-19 and those who did not, admitted to hospitals in Buenos Aires Province, Argentina, throughout the pandemic.

Methods This is a multicenter, retrospective cohort study of 2-month duration beginning on June 1, 2020, including unselected, consecutive adult patients with diagnosed COVID-19, admitted to 215 hospitals with pneumonia. Epidemiological and clinical variables were registered in the Provincial Hospital Bed Management System. Convalescent plasma was supplied as part of a centralized, expanded access program.

Results We analyzed 3,529 patients with pneumonia, predominantly male, aged 62±17, with arterial hypertension and diabetes as main comorbidities; 51.4% were admitted to the ward, 27.1% to the Intensive Care Unit (ICU), and 21.7% to the ICU with mechanical ventilation requirement (ICU-MV). 28-day mortality was 34.9%; and was 26.3%, 30.1% and 61.4% for ward, ICU and ICU-MV patients. Convalescent plasma was administered to 868 patients (24.6%); their 28-day mortality was significantly lower (25.5% vs. 38.0%, p<0.001). No major adverse effects occurred.

Logistic regression analysis identified age, ICU admission with and without MV requirement, diabetes and preexistent cardiovascular disease as independent predictors of 28-day mortality, whereas convalescent plasma administration acted as a protective factor.

Conclusions Our study suggests that the administration of convalescent plasma in COVID-19 pneumonia admitted to the hospital might be associated with decreased mortality.

Key Points

  • Preliminary evidence showed that convalescent plasma might be beneficial in COVID-19.

  • In a cohort of 3,529 patients with pneumonia due to COVID-19, convalescent plasma was administered to 868 patients, without major adverse effects.

  • Convalescent plasma was independently associated with decreased mortality.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

We did not register our study EFFECT OF CONVALESCENT PLASMA ON MORTALITY IN PATIENTS WITH COVID-19 PNEUMONIA since it was an observational study and not an intervention one

Funding Statement

No funding was received for this study.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Central Ethics Committee of the Ministry of Health of Buenos Aires Province (Expedient 2020-14965594). The resolution 103/2017 of the Ministry of Health of the Province of Buenos Aires establishes the obligation of registration and accreditation of all the Institutional Ethics Committees at the Central Ethics Committee of the Ministry of Health the Province of Buenos Aires; which is not associated with any institution or organization except the same Ministry, as it is the Ethics Committee of the said body, and evaluates all projects developed by institutions of the Ministry. In the protocol of the present study, the Central Ethics Committee acts as an Institutional Evaluation Committee in use of the powers provided for by Decree 3385/08 as a research project, in which the Ministry of Health of the Province of Buenos Aires acts both as sponsor and center. The Central Committee established that this observational study had an adequate risk- benefit ratio and requested the anonymization of data. The administration of convalescent plasma required signed consent from each patient or legal representative, according to CROCPD-BA regulations (Expedient 2919/2123/2020).

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

I declare that all the data referred to in the manuscript are available.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 09, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
EFFECT OF CONVALESCENT PLASMA ON MORTALITY IN PATIENTS WITH COVID-19 PNEUMONIA
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
EFFECT OF CONVALESCENT PLASMA ON MORTALITY IN PATIENTS WITH COVID-19 PNEUMONIA
Martín R. Salazar, Soledad E. González, Lorena Regairaz, Noelia S. Ferrando, Veronica V. González Martínez, Patricia M. Carrera Ramos, Laura Muñoz, Santiago A. Pesci, Juan M. Vidal, Nicolas Kreplak, Elisa Estenssoro
medRxiv 2020.10.08.20202606; doi: https://doi.org/10.1101/2020.10.08.20202606
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
EFFECT OF CONVALESCENT PLASMA ON MORTALITY IN PATIENTS WITH COVID-19 PNEUMONIA
Martín R. Salazar, Soledad E. González, Lorena Regairaz, Noelia S. Ferrando, Veronica V. González Martínez, Patricia M. Carrera Ramos, Laura Muñoz, Santiago A. Pesci, Juan M. Vidal, Nicolas Kreplak, Elisa Estenssoro
medRxiv 2020.10.08.20202606; doi: https://doi.org/10.1101/2020.10.08.20202606

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (161)
  • Allergy and Immunology (414)
  • Anesthesia (90)
  • Cardiovascular Medicine (857)
  • Dentistry and Oral Medicine (159)
  • Dermatology (97)
  • Emergency Medicine (248)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (393)
  • Epidemiology (8557)
  • Forensic Medicine (4)
  • Gastroenterology (383)
  • Genetic and Genomic Medicine (1749)
  • Geriatric Medicine (167)
  • Health Economics (372)
  • Health Informatics (1239)
  • Health Policy (620)
  • Health Systems and Quality Improvement (467)
  • Hematology (196)
  • HIV/AIDS (372)
  • Infectious Diseases (except HIV/AIDS) (10292)
  • Intensive Care and Critical Care Medicine (553)
  • Medical Education (192)
  • Medical Ethics (51)
  • Nephrology (211)
  • Neurology (1676)
  • Nursing (97)
  • Nutrition (249)
  • Obstetrics and Gynecology (326)
  • Occupational and Environmental Health (450)
  • Oncology (928)
  • Ophthalmology (263)
  • Orthopedics (101)
  • Otolaryngology (172)
  • Pain Medicine (112)
  • Palliative Medicine (40)
  • Pathology (252)
  • Pediatrics (534)
  • Pharmacology and Therapeutics (248)
  • Primary Care Research (207)
  • Psychiatry and Clinical Psychology (1765)
  • Public and Global Health (3835)
  • Radiology and Imaging (623)
  • Rehabilitation Medicine and Physical Therapy (320)
  • Respiratory Medicine (520)
  • Rheumatology (208)
  • Sexual and Reproductive Health (166)
  • Sports Medicine (158)
  • Surgery (190)
  • Toxicology (36)
  • Transplantation (101)
  • Urology (76)